Patents by Inventor Bianka Prinz

Bianka Prinz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-IL-27 ANTIBODIES AND USES THEREOF
    Publication number: 20230042258
    Abstract: The present disclosure relates to anti-IL-27 antibodies, and antigen-binding portions thereof. The disclosure also relates to methods for treating or ameliorating one or more symptoms of a disease, such as cancer, by administering the antibodies or antigen-binding portion thereof. The disclosure also relates to methods for detecting IL-27 in, for example, a subject or a sample.
    Type: Application
    Filed: April 6, 2022
    Publication date: February 9, 2023
    Applicants: Surface Oncology, Inc., Adimab LLC
    Inventors: Jonathan HILL, Scott CHAPPEL, Michael GLADSTONE, Bianka PRINZ, Andrew LAKE, Christine MILLER, Kerry WHITE, Jing HUA, Pamela M. HOLLAND, Matthew RAUSCH, Devapregasan MOODLEY
  • ANTIBODY MOLECULES TO CD73 AND USES THEREOF
    Publication number: 20230039109
    Abstract: Antibody molecules that bind to CD73 are disclosed. The anti-CD73 antibody molecules can be used to treat, prevent and/or diagnose cancer.
    Type: Application
    Filed: March 15, 2022
    Publication date: February 9, 2023
    Inventors: Bianka Prinz, Jerry M. Thomas, Ansgar Brock, Viviana Cremasco, Catherine Anne Sabatos-Peyton, Glenn Dranoff, Scott Chappel, Andrew Lake, Alison Paterson, Rachel W. O'Connor, Michael Warren, Pamela Holland, Kulandayan Kasi Subramanian, Helena Marie-Louise Fjaellskog, Dirksen Bussiere, Mikias Woldegiorgis, Wei Shu, John Delmas Venable, III, Michael Gladstone, Jonathan Hill, Christine Miller
  • ANTI-CD19 ANTIBODIES AND MULTI-SPECIFIC BINDING PROTEINS
    Publication number: 20230037815
    Abstract: Provided herein are anti-CD 19 antibodies and multi-specific binding proteins that bind CD 19, CD3, and serum albumin. Also provided are pharmaceutical compositions comprising these antibodies or multi-specific binding proteins, expression vectors and host cells for making these antibodies or multi-specific binding proteins, and methods of use of these antibodies or multi-specific binding proteins in treating cancers.
    Type: Application
    Filed: December 11, 2020
    Publication date: February 9, 2023
    Inventors: Patrick A. Baeuerle, Jennifer Michaelson, Bochong Li, Naveen Mehta, Jonathan Belk, Nathan Sharkey, Bianka Prinz, Bradley M. Lunde, Nga Rewa Houston
  • ANTI-SERUM ALBUMIN ANTIBODIES
    Publication number: 20230032087
    Abstract: The invention relates to anti-serum albumin antibodies and multi-specific binding proteins comprising the same. The invention also relates to pharmaceutical compositions comprising the antibodies or multi-specific binding proteins, expression vectors and host cells for making the antibodies or multi-specific binding proteins, and methods of use of the antibodies or multi-specific binding proteins in treatment of diseases or disorders.
    Type: Application
    Filed: December 11, 2020
    Publication date: February 2, 2023
    Inventors: Patrick A. Baeuerle, Jennifer Michaelson, Bochong Li, Naveen Mehta, Bianka Prinz, Bradley M. Lunde, Nga Rewa Houston
  • CD38 modulating antibody
    Patent number: 11542338
    Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD38. In particular, the present disclosure provides sequences of anti-human CD38 antibodies. Antibodies and antigen-binding portions thereof including such sequences present features compatible with pharmaceutical manufacturing and development can be provided as fully human antibodies (e.g., fully human monoclonal antibodies or antigen-binding fragments) that can be useful for medical methods and compositions, in particular for treating cancer.
    Type: Grant
    Filed: August 16, 2018
    Date of Patent: January 3, 2023
    Assignee: BLACK BELT THERAPEUTICS LIMITED
    Inventors: Anne Goubier, Josephine Salimu, Kevin Moulder, Beatriz Goyenechea Corzo, Simone Filosto, Pascal Merchiers, Nina Eissler, Hemanta Baruah, Bianka Prinz
  • Human PD-L1 antibodies and methods of use therefor
    Patent number: 11525002
    Abstract: The present disclosure is directed to antibodies binding to PD-L1 and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L1.
    Type: Grant
    Filed: October 10, 2018
    Date of Patent: December 13, 2022
    Assignee: Board of Regents, The University of Texas System
    Inventors: Michael A. Curran, Carlo Toniatti, Ashvin R. Jaiswal, Dongxing Zha, Kui Voo, Bianka Prinz, Nadthakarn Boland
  • Monoclonal antibodies against HER2 epitope and methods of use thereof
    Patent number: 11518812
    Abstract: This invention provides fully human monoclonal antibodies that recognize HER2. The invention further provides methods of using such monoclonal antibodies in a variety of therapeutic, diagnostic, and prophylactic indications.
    Type: Grant
    Filed: October 2, 2019
    Date of Patent: December 6, 2022
    Assignee: Mersana Therapeutics, Inc.
    Inventors: Natalya D. Bodyak, Michael J. DeVit, Eric M. Krauland, Timothy B. Lowinger, Peter U. Park, Bianka Prinz, Aleksandr V. Yurkovetskiy
  • MULTI-SPECIFIC BINDING PROTEINS THAT BIND CD33, NKG2D, AND CD16, AND METHODS OF USE
    Publication number: 20220380459
    Abstract: Multi-specific binding proteins that bind to and kill human cancer cells expressing CD33 (Siglec-3) are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of CD33 expressing cancer. The invention relates to multi-specific binding proteins that bind to human cancer cells expressing CD33, and exhibit high potency and maximum lysis of target cells compared to anti-CD33 monoclonal antibodies.
    Type: Application
    Filed: May 3, 2022
    Publication date: December 1, 2022
    Inventors: Gregory P. Chang, Ann F. Cheung, Asya Grinberg, Dhruv Kam Sethi, William Haney, Bianka Prinz, Bradley M. Lunde, Ronnie Wei, Daniel Fallon, Steven O'Neil
  • ENGINEERED PH-DEPENDENT ANTI-CD3 ANTIBODIES, AND METHODS FOR THEIR GENERATION AND USE
    Publication number: 20220380463
    Abstract: Engineered pH-dependent anti-CD3 binding domains and antibodies and/or antigen-binding domains comprising same, including multispecific antibodies, with, inter alia, desirable T-cell activation and (re)directed target cell killing potency and developability, profiles are provided, as well as methods for their identification, isolation, and generation, and methods for their preparation and use.
    Type: Application
    Filed: June 8, 2020
    Publication date: December 1, 2022
    Inventors: James GEOGHEGAN, Bianka PRINZ, Robert PEJCHAL
  • Anti-coagulation factor XI antibodies
    Patent number: 11512142
    Abstract: Antibodies that bind the apple 3 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa as well as activation of FIX by FXIa are described.
    Type: Grant
    Filed: May 1, 2020
    Date of Patent: November 29, 2022
    Assignees: Merck Sharp & Dohme LLC, Adimab LLC
    Inventors: Zhu Chen, Kenneth Ellsworth, James Milligan, Elizabeth Oldham, Dietmar Seiffert, Bianka Prinz
  • Anti-CD39 Antibody Compositions and Methods
    Publication number: 20220372160
    Abstract: The invention provides anti-CD39 antibody compositions and their use in treating cancer. In some embodiments, an isolated anti-CD39 antibody is provided. Such an isolated anti-CD39 antibody binds to human CD39, wherein the antibody is optionally fully human or humanized. In some embodiments, the disclosure provides a method of enhancing, increasing and/or sustaining an anti-tumor immune response in a subject comprising administering the antibody or composition described herein to a subject having a tumor.
    Type: Application
    Filed: September 15, 2020
    Publication date: November 24, 2022
    Applicant: Surface Oncology, Inc.
    Inventors: Scott CHAPPEL, Andrew LAKE, Michael WARREN, Austin DULAK, Erik DEVEREAUX, Pamela M. HOLLAND, Tauqeer ZAIDI, Matthew RAUSCH, Bianka Prinz, Nels P. NIELSON, Sonia DAS, Alison M. O'Neill
  • Anti-coagulation factor XI antibodies
    Patent number: 11485794
    Abstract: Antibodies that bind the apple 3 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa as well as activation of FIX by FXIa are described.
    Type: Grant
    Filed: May 1, 2020
    Date of Patent: November 1, 2022
    Assignees: Merck Sharp & Dohme LLC, Adimab, LLC
    Inventors: Zhu Chen, Kenneth Ellsworth, James Milligan, Elizabeth Oldham, Dietmar Seiffert, Bianka Prinz
  • Anti-coagulation factor XI antibodies
    Patent number: 11479615
    Abstract: Antibodies that bind the apple 3 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa as well as activation of FIX by FXIa are described.
    Type: Grant
    Filed: May 1, 2020
    Date of Patent: October 25, 2022
    Assignees: Merck Sharp & Dohme LLC, Adimab, LLC
    Inventors: Zhu Chen, Kenneth Ellsworth, James Milligan, Elizabeth Oldham, Dietmar Seiffert, Bianka Prinz
  • ANTI-IL-27 ANTIBODIES AND USES THEREOF
    Publication number: 20220259299
    Abstract: The present disclosure relates to anti-IL-27 antibodies, and antigen-binding portions thereof. The disclosure also relates to methods for treating or ameliorating one or more symptoms of a disease, such as cancer, by administering the antibodies or antigen-binding portion thereof. The disclosure also relates to methods for detecting IL-27 in, for example, a subject or a sample.
    Type: Application
    Filed: September 25, 2019
    Publication date: August 18, 2022
    Applicant: SURFACE ONCOLOGY, INC.
    Inventors: Jonathan HILL, Scott CHAPPEL, Michael GLADSTONE, Bianka PRINZ, Andrew LAKE, Christine MILLER, Kerry WHITE, Jing HUA, Pamela M. HOLLAND, Matthew RAUSCH, Devapregasan MOODLEY, Gege TAN
  • Anti-TIGIT antibodies
    Patent number: 11401339
    Abstract: Isolated antibodies that bind to human TIGIT (T-cell immunoreceptor with Ig and ITIM domains) are provided. In some embodiments, the antibody has a binding affinity (KD) for human TIGIT of less than 5 nM. In some embodiments, the anti-TIGIT antibody blocks binding of CD155 and/or CD112 to TIGIT. In some embodiments, the antibodies are afucosylated.
    Type: Grant
    Filed: August 22, 2019
    Date of Patent: August 2, 2022
    Assignee: Seagen Inc.
    Inventors: Julia C. Piasecki, Courtney Beers, Scott Peterson, Bianka Prinz, Shyra Gardai
  • Anti-CD112R Compositions and Methods
    Publication number: 20220162317
    Abstract: The invention provides anti-CD112R antibody compositions and their use in treating cancer.
    Type: Application
    Filed: November 19, 2021
    Publication date: May 26, 2022
    Inventors: Bianka PRINZ, Nadthakarn BOLAND, Kevin SCHUTZ, John BUKOWSKI, Jennifer SYMONDS, James MOHAN, Marisella Panduro SICHEVA
  • PROTEINS BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN
    Publication number: 20220153848
    Abstract: Multi-specific binding proteins that bind NKG2D receptor, CD 16, and a tumor-associated antigen selected from c-MET, KIT, F3, IGF1R, Lewis Y, MUC13, MUC4, MCAM, LRRC32, sialyl-Tn, gpA33, GD3, GM2, EPHA3, TNFRSF10A, TNFSF11, CD74, and PMEL are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer.
    Type: Application
    Filed: August 8, 2019
    Publication date: May 19, 2022
    Inventors: Gregory P. CHANG, Ann F. CHEUNG, Jinyan DU, Daniel FALLON, Asya GRINBERG, William HANEY, Bradley M. LUNDE, Steven O'NEIL, Bianka PRINZ, Ronnie WEI
  • Anti-IL-27 antibodies and uses thereof
    Patent number: 11332524
    Abstract: The present disclosure relates to anti-IL-27 antibodies, and antigen-binding portions thereof. The disclosure also relates to methods for treating or ameliorating one or more symptoms of a disease, such as cancer, by administering the antibodies or antigen-binding portion thereof. The disclosure also relates to methods for detecting IL-27 in, for example, a subject or a sample.
    Type: Grant
    Filed: March 22, 2019
    Date of Patent: May 17, 2022
    Assignees: Surface Oncology, Inc., Adimab LLC
    Inventors: Jonathan Hill, Scott Chappel, Michael Gladstone, Bianka Prinz, Andrew Lake, Christine Miller, Kerry White, Jing Hua, Pamela M. Holland, Matthew Rausch, Devapregasan Moodley
  • CD38 ANTIBODY
    Publication number: 20220135697
    Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD38. In particular, the present disclosure provides sequences of anti-human CD38 antibodies. Antibodies and antigen-binding portions thereof including such sequences present features compatible with pharmaceutical manufacturing and development can be provided as fully human antibodies (e.g., fully human monoclonal antibodies or antigen-binding fragments) that can be useful for medical methods and compositions, in particular for treating cancer.
    Type: Application
    Filed: January 18, 2022
    Publication date: May 5, 2022
    Inventors: Anne GOUBIER, Josephine SALIMU, Kevin MOULDER, Beatriz GOYENECHEA CORZO, Simone FILOSTO, Pascal MERCHIERS, Nina EISSLER, Hemanta BARUAH, Bianka PRINZ
  • Antibody molecules to CD73 and uses thereof
    Patent number: 11312783
    Abstract: Antibody molecules that bind to CD73 are disclosed. The anti-CD73 antibody molecules can be used to treat, prevent and/or diagnose cancer.
    Type: Grant
    Filed: June 21, 2018
    Date of Patent: April 26, 2022
    Assignees: Novartis AG, SURFACE ONCOLOGY, INC.
    Inventors: Bianka Prinz, Jerry M. Thomas, Ansgar Brock, Scott Chappel, Andrew Lake, Alison Paterson, Rachel W. O'Connor, Michael Warren, Pamela Holland, Dirksen Bussiere, Mikias Woldegiorgis, Wei Shu, John Delmas Venable, Michael Gladstone, Jonathan Hill, Christine Miller